



ICD-10 & Other Coding Revisions to National Coverage Determinations: April 2025 Update (CR 1 of 2)

Related CR Release Date: October 24, 2024	MLN Matters Number: MM13818
Effective Date: April 1, 2025, or as noted in CR 13818	Related Change Request (CR) Number: CR 13818
Implementation Date: November 26, 2024: BRs 2 & 7; April 7, 2025: BRs 1, 3, 4, 5, 6 & 8	Related CR Transmittal Number: R12903OTN

Related CR Title: International Classification of Diseases, 10th Revision (ICD-10) and Other Coding Revisions to National Coverage Determinations (NCDs)—April 2025 (CR 1 of 2)

Affected Providers

- Physicians
- Suppliers
- Other providers billing Medicare Administrative Contractors (MACs) for services they provide to Medicare patients

Action Needed

Make sure your billing staff knows about:

- Newly available codes
- Recent coding changes
- National Coverage Determination (NCD) coding information

Background

CR 13818 is a maintenance update of ICD-10 conversions and other coding updates specific to NCDs. These NCD coding changes are the result of newly available codes, coding revisions to NCDs released separately, or coding feedback received.

Translations from ICD-9 to ICD-10 aren't consistent 1-to-1 matches, nor are all ICD-10 codes appearing in a complete General Equivalence Mappings mapping guide or other mapping guides appropriate when reviewed against individual NCD policies. Also, for policies that allow MAC discretion, NCDs may change based on current review of those NCDs against ICD-10 coding. For these reasons, some ICD-9 codes that were appropriate before ICD-10 implementation are no longer valid.

Relevant NCD coding changes in CR 13818 include:

- NCD 30.3.3 — Acupuncture for Chronic Low Back Pain (cLBP)
- NCD 80.2 — Photodynamic Therapy
- NCD 80.2.1 — Ocular Photodynamic Therapy (OPT)
- NCD 80.3 — Photosensitive Drugs
- NCD 80.3.1 — Verteporfin
- NCD 110.4 — Extracorporeal Photopheresis
- NCD 110.18 — Aprepitant for Chemotherapy-Induced Emesis
- NCD 110.21 — Erythropoiesis Stimulating Agents (ESAs) in Cancer and Related Neoplastic Conditions
- NCD 110.23 — Stem Cell Transplantation
- NCD 110.24 — Chimeric Antigen Receptor (CAR) T-cell Therapy
- NCD 190.3 — Cytogenetic Studies

[Previous NCD coding changes](#) are available. Also, see the [NCD spreadsheets](#) for CR 13818.

We didn't include any policy changes in this ICD-10 quarterly update. We share NCD policy changes using the current, longstanding NCD process.

Your MAC will adjust any claims processed in error associated with CR 13818 that you bring to their attention.

More Information

We issued [CR 13818](#) to your MAC as the official instruction for this change. For more information, find your [MAC's website](#).

Document History

Date of Change	Description
November 5, 2024	Initial article released.

View the [Medicare Learning Network® Content Disclaimer and Department of Health & Human Services Disclosure](#).

The Medicare Learning Network®, MLN Connects®, and MLN Matters® are registered trademarks of the U.S. Department of Health & Human Services (HHS).